medigraphic.com

2011, Number 2

<< Back Next >>

Rev Fac Med UNAM 2011; 54 (2)

Serotonin syndrome

Carrillo ER, Garnica EMA, Rocha RMG, Carrillo CCA

Language: Spanish
References: 25
Page: 46-53
PDF size: 372.85 Kb.


ABSTRACT

The serotonin syndrome (SS) is characterized by a spectrum of signs characterized by autonomic dysfunction, neuromuscular impairment, and alterations in mental status. The diagnosis of the serotonin syndrome is clinical and by laboratory evaluation. Treatment is with active cooling and benzodiazepines to control agitation, and intubation, especially in patients with severe hyperthermia and delirium. The mainstay of pharmacologic intervention is cyproheptadine, a centrally acting H1-antagonist, with a prominent peripheral 5-HT2A antagonism. The drug is only available orally, andif the patient is unable to swallow, the drug should be administered nasogastrically. The objective of this paper is report a case of Serotonin Syndrome and review the literature related to this disease.


REFERENCES

  1. Boyer E, Shannon M. Current concepts: the serotonin syndrome. N Engl J Med. 2005;352:1112-23.

  2. Holmann P, Weissman MM, Zubenko GS. Genetics of earlyonset mayor depression. A J Psychiatry. 2006;163:109-14.

  3. Belmaker RH, Agam G Schwlad M. Neurotrophin levels in postmortem brain of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res mol. 2005;236;29-39.

  4. Nisijima K, Shioda K, Iwamura T. Neuroleptic malignant syndrome and serotonin syndrome. Prog Brain Res. 2007;162: 81-104.

  5. Ananth J, Parameswaran S, Gunatilake S. Side effects of atypical antipsychotic drugs. Curr Pharm Des. 2004;10(18):2219-29.

  6. Caroff SN, Mann SC. Neuroleptic malignant syndrome and malignant hyperthermia. Anaesth Intensive Care. 1993;21(4): 477-8.

  7. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999;13(1):100-9.

  8. Demirkiran M, Jankivic J, Dean JM. Ectasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol. 1996;19:157-64.

  9. Mahlber R, Kunz D, Sarse J, Kircheiner J. Serotonin syndrome with tramadol plus citalopram. Am J Psych. 2004;161:1129-32.

  10. Houilihan DJ. Serotonin syndrome from coadministration of tramadol, enlafaxine and mirtazapine. Ann Pharmacother. 2004; 38:411-3.

  11. Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K. Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level correlated symptomatology. J Clin Psychopharmacol. 2002;22:440-2.

  12. Chapra P, Ng C, Schweitzer I. Serotonin syndrome with fluoxetine and olanzapine. World J Biol Psychiatry. 2004;2:114-5.

  13. Duggal HS, Fetchko J. Serotonin syndrome and atypical antipsychotic. Am J Psychiatry. 2002;159:672-3.

  14. Birnes P, Coopin D, Schmitt, Lauque D. Serotonin syndrome: a brief review. CMAJ. 2003;168:1439-42.

  15. Isbister GK. Serotonin syndrome, mydriasis, and cyproheptadine. Ann Pharmacother. 2001;35:1672-3.

  16. Ali SZ, Taguchi A, Rosenberg H. Malignant hyperthermia. Best Pract Res Clin Anesthesiol. 2003;17:519-33.

  17. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999;13:100-9.

  18. Kapur S, Zipursky RB, Jones C, Wilson AA, Da Silva JD, Houle S. Cyproheptadine: a potent in vivo serotonin antagonist. AmJ Psychiatry. 1997;154:884.

  19. Kaneda Y, Ohmori T, Fujii A. The serotonin syndrome: investigation using the Japanese version of the Serotonin Syndrome Scale. Psychiatry Res. 2001;105:135-42.

  20. Nisijima K, Shioda K, Yoshino T, Takano K, Kato S. Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome. Neurochem Int. 2003;43:155-64.




2020     |     www.medigraphic.com